Skip to main content
Effective Health Care Program

Management of Infantile Hemangioma


This CME activity is hosted on the Baylor College of Medicine CME Web site (

Course Overview

Infantile hemangioma (IH) is the most common tumor of childhood and is estimated to affect about 4 to 5 percent of children. With a course of expectant observation, many patients experience a complete involution without significant sequelae. However, in a fraction of patients, early referral for treatment is important. Currently available treatments include pharmacological interventions (such as beta-blockers and steroids) and surgical interventions (such as laser therapy or excision in appropriate cases). The beta-blocker propranolol was approved by the U.S. Food and Drug Administration (FDA) in March 2014 as a treatment for IH and is typically the first-line treatment choice in children without contraindications. Uncertainty remains around which interventions might be most beneficial as first-line therapies, when alternative or adjunctive therapies are appropriate after first-line treatment is unsuccessful, and how the disease site informs treatment decisions. This review aims to address some of these issues.

Educational Objectives

At the conclusion of this activity, the participant should be able to:

  • Describe the evidence regarding the efficacy, comparative effectiveness, and harms of therapies for infantile hemangioma.
  • Describe the gaps in the current evidence base and areas needing additional research regarding the comparative effectiveness of treatments for infantile hemangioma.

Target Audience

This CME activity is designed to meet the educational needs of primary care physicians, pediatricians, pediatric dermatologists, pediatric otolaryngologists, surgeons, physician assistants, nurse practitioners, and other health care professionals who treat children with infantile hemangioma.

Method of Participation

This activity is in PDF and HTML formats and is accompanied by references linked to PubMed abstracts.

To receive a maximum of 0.50 AMA PRA Category 1 Credit(s)™ you should:

  • View the materials in this enduring material.
  • Complete the posttest (you must answer 4 out of 5 questions correctly).
  • Complete and submit the CME registration and evaluation forms.

The estimated time to complete this activity, including review of the materials, is 0.50 hour(s).

Accreditation/Credit Designation

Baylor College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Baylor College of Medicine designates this enduring material activity for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Term of Approval

June 2016 through June 2018. Original release date: June 2016

Acknowledgement of Support

This CME activity is supported by a contract, HHSA290201410015C, from the Agency for Healthcare Research and Quality.